Why IDEXX Laboratories, Inc. Jumped Higher Today

Image source: IDEXX Laboratories.

What happened

IDEXX Laboratories (NASDAQ: IDXX) was up almost 14% at 3:33 p.m. EST after announcing better-than-expected fourth-quarter earnings and raising its 2017 earnings guidance.

So what

More From Fool.com

Motley Fool Founders Issue New Stock Buy Alert

Forget GE! Heres how to play the largest growth opportunity in history

Forget Apple! Heres a Better Stock to Buy

He Made 21,078% Buying Amazon. Heres His New Pick

Revenue during the quarter increased 11% year over year on the back of the company's tests for companion animals, which grew 13%. The number of instruments sold increased 15% year over year, while the growing installed base helped drive a 17% jump in sales of the consumables used in the instruments. Revenue from laboratory tests performed by IDEXX -- rather than in the veterinarian's office -- increased 12% year over year. The only downside to the segment was for IDEXX's rapid assay products, which only grew 6% year over year.

Tests for livestock, poultry, and dairy were down 1%, but fortunately this group makes up an ever-shrinking amount of IDEXX's revenue. The water-testing segment grew 1%, but it's even smaller.

The increased sales help IDEXX increase operating margins, allowing earnings to grow faster than revenue. In the fourth quarter, earnings per share increased 21% year over year to $0.58. For the year, that put earnings at $2.44 per share, substantially higher than the guidance of $2.35 to $2.39 per share announced at the end of the third quarter.

Now what

Management maintained its previously announced revenue guidance of $1.91 billion to $1.935 billion, but increased its guidance for earnings per share because of new accounting standards. The company is now looking for 2017 earnings per share in the $2.85 to $3.01 range, a 17% to 23% increase over last year's earnings.

10 stocks we like better than IDEXX Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Idexx Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of January 4, 2017

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Idexx Laboratories. The Motley Fool has a disclosure policy.